Arthur Tzianabos has sold stock and made no open-market buys since Jun 2019

Arthur O. Tzianabos, Ph.D. (age 62) is Interim Executive Chairman of the Board of Directors at Stoke Therapeutics, Inc. (STOK), a role he assumed on March 19, 2025, following his prior positions as Board Chair (since September 2024) and director (since September 2018).( He recently engaged in insider trading activity, exercising options for 3,955 shares at $8.33 and selling 4,355 shares at approximately $40.( Concurrently, he serves as CEO of Lifordi Immunotherapeutics (since June 2023) and Venture Partner at 5AM Ventures (since September 2022).(

Tzianabos has a distinguished career in biotechnology, including leading Homology Medicines as President & CEO from 2016 to 2022, guiding it from inception through its IPO with a focus on genetic medicines.( Previously, he held senior roles at Shire Plc developing rare disease treatments, served as President & Chief Scientific Officer at OvaScience, and was faculty at Harvard Medical School for 15 years as an associate professor with over 80 publications.( He holds a B.S. in biology from Boston College and a Ph.D. in microbiology from the University of New Hampshire.( Additional board roles include Q32 Bio and formerly Akouos (acquired by Lilly in 2022).(

Written by Perplexity from public sources.